Table 11. Uptake of Risk-reducing Salpingo-oophorectomy (RRSO) and/or Gynecologic Screening Among BRCA1 and BRCA2 Mutation Carriers
| Study Citation | Study Population | Uptake of RRSO | Uptake of Gynecologic Screening | Length of Follow-up | Comments |
| United States | |||||
| [200] | Carriers (n = 100)a | Carriers 65% | CA125 | Mean 5.3 y | Predictors of RRSO were being ≥40 y and diagnosis of breast cancer more than 10 y ago. |
| Carriers 56% | |||||
| Noncarriers 12% | |||||
| Noncarriers (n = 52)a | Noncarriers 1.9% | Uninformative 33% | |||
| TVUS | |||||
| Carriers 42% | |||||
| Uninformative (n = 203)a | Uninformative 13.3% | Noncarriers 20% | |||
| Uninformative 26% | |||||
| [201] | Carriers (n = 146)a | Carriers 32% | Not applicable | 12 mo | |
| [202] | Carriers (n = 240)b | Carriers 51% | Not applicable | Mean 3.7 y | Women opting for RRSO were <60 y, had a prior diagnosis of breast cancer, and also underwent RRM. |
| Median time to RRSO: 123 days from receiving results. | |||||
| [207] | Carriers (n = 179)a, | Carriers 50.3% | CA 125 | Mean 24.8 mo; range 1.6–66.0 mo | Women undergoing RRSO were older and more likely to have a personal history of breast cancer. |
| Carriers 67.6% | |||||
| TVUS | |||||
| Carriers 72.9% | |||||
| International | |||||
| [208] | Carriers (N = 306)b | Carriers 57% | Not evaluated | Mean 47.8 mo post-oophorectomy | Median age at time of RRSO = 47 y. One occult fallopian tube cancer was detected at the time of RRSO. One peritoneal carcinoma was diagnosed 26 mo post RRSO. |
| [204] | Carriers (n = 101)a | Carriers 42.6% | TVUS | 5 y | RRSO uptake increased with age. Having undergone RRSO did not alter breast cancer risk perception Noncarriers often continued screening. |
| Noncarriers (n = 145)a | Noncarriers 2% | Noncarriers 43.2% | |||
| [205] | Carriers (n = 70)a | Carriers 29% | CA 125 | 3 y | |
| Carriers 0% | |||||
| TVUS | |||||
| Carriers 67% | |||||
| [209] | Carriers (N = 160)a, b | Carriers 74% | Carriers 26% | 12 mo | Women undergoing RRSO had lower education levels, viewed ovarian cancer as incurable and believed strongly in the benefits of RRSO. |
| Specific method(s) of gynecological screening not reported. | |||||
| [206] | Carriers (N = 2,677)a | Carriers 57% | Not applicable | 3.9 y; range 1.5–10.3 y | Large differences in uptake of risk management options by country. |
| [210] | Carriers (N = 537)c | Carriers 55% | Not applicable | Minimum 6 mo; median 36 mo | RRSO greatest in parous women >40 y. |
| CA 125 = cancer antigen 125; RRM = risk-reducing mastectomy; TVUS = transvaginal ultrasound. | |||||
| aSelf-report as data source. | |||||
| bMedical records as data source. | |||||
| cData source not specified. |
References
- Schwartz MD, Isaacs C, Graves KD, et al.: Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer 118 (2): 510-7, 2012. [PUBMED Abstract]
- O'Neill SC, Valdimarsdottir HB, Demarco TA, et al.: BRCA1/2 test results impact risk management attitudes, intentions, and uptake. Breast Cancer Res Treat 124 (3): 755-64, 2010. [PUBMED Abstract]
- Beattie MS, Crawford B, Lin F, et al.: Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers 13 (1): 51-6, 2009. [PUBMED Abstract]
- Julian-Reynier C, Mancini J, Mouret-Fourme E, et al.: Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations. Eur J Hum Genet 19 (5): 500-6, 2011. [PUBMED Abstract]
- Phillips KA, Jenkins MA, Lindeman GJ, et al.: Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clin Genet 70 (3): 198-206, 2006. [PUBMED Abstract]
- Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al.: International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122 (9): 2017-22, 2008. [PUBMED Abstract]
- Scheuer L, Kauff N, Robson M, et al.: Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20 (5): 1260-8, 2002. [PUBMED Abstract]
- Rhiem K, Foth D, Wappenschmidt B, et al.: Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 283 (3): 623-7, 2011. [PUBMED Abstract]
- Madalinska JB, van Beurden M, Bleiker EM, et al.: Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J Clin Oncol 25 (3): 301-7, 2007. [PUBMED Abstract]
- Friebel TM, Domchek SM, Neuhausen SL, et al.: Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer 7 (11): 875-82, 2007. [PUBMED Abstract]
